1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Antibiotic Pioneers Increasingly Looking to Emerging Markets For Partners

China Becoming A ‘Hub’ For Antibacterial Development And Commercialization

 
• By Sten Stovall

Small- to medium-sized drug makers developing new products for resistant infections are increasingly partnering with players in emerging markets such as China because of the absence of workable risk/reward systems in rich countries, according to a report by The Access To Medicine Foundation.

Trend Reflects Lack Of Viable Risk / Reward Systems In Rich Countries • Source: Alamy

Caught between the urgent clinical need for their R&D candidates and the lack of financing and revenue, some small- and medium-sized companies involved in making novel antimicrobials are now exploring development and commercialization pathways in low- and middle-income countries, notably in China and India, new research shows. 

A report by The Access To Medicine Foundation, an independent non-profit organisation based in the Netherlands, released on 10 June...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.